Division of Gastroenterology and Hepatology, Stanford University, Stanford, CA, USA.
Enable Medicine, Menlo Park, CA, USA.
Nat Cancer. 2024 Oct;5(10):1534-1556. doi: 10.1038/s43018-024-00828-8. Epub 2024 Sep 20.
Hepatocellular carcinoma (HCC) frequently recurs from minimal residual disease (MRD), which persists after therapy. Here, we identified mechanisms of persistence of residual tumor cells using post-chemoembolization human HCC (n = 108 patients, 1.07 million cells) and a transgenic mouse model of MRD. Through single-cell high-plex cytometric imaging, we identified a spatial neighborhood within which PD-L1 + M2-like macrophages interact with stem-like tumor cells, correlating with CD8 T cell exhaustion and poor survival. Further, through spatial transcriptomics of residual HCC, we showed that macrophage-derived TGFβ1 mediates the persistence of stem-like tumor cells. Last, we demonstrate that combined blockade of Pdl1 and Tgfβ excluded immunosuppressive macrophages, recruited activated CD8 T cells and eliminated residual stem-like tumor cells in two mouse models: a transgenic model of MRD and a syngeneic orthotopic model of doxorubicin-resistant HCC. Thus, our spatial analyses reveal that PD-L1 macrophages sustain MRD by activating the TGFβ pathway in stem-like cancer cells and targeting this interaction may prevent HCC recurrence from MRD.
肝细胞癌 (HCC) 常由治疗后残留的微小残留病灶 (MRD) 复发而来。在这里,我们通过经化疗栓塞后的人 HCC(n=108 例患者,107 万个细胞)和 MRD 的转基因小鼠模型,确定了残留肿瘤细胞持续存在的机制。通过单细胞高多重细胞计量成像,我们鉴定了一个 PD-L1+M2 样巨噬细胞与干细胞样肿瘤细胞相互作用的空间邻域,与 CD8 T 细胞耗竭和不良预后相关。此外,通过残留 HCC 的空间转录组学分析,我们表明巨噬细胞衍生的 TGFβ1 介导了干细胞样肿瘤细胞的持续存在。最后,我们证明了 PD-L1 和 TGFβ 的联合阻断可以排除免疫抑制性巨噬细胞,招募激活的 CD8 T 细胞,并在两种小鼠模型(MRD 的转基因模型和多柔比星耐药 HCC 的同基因原位模型)中消除残留的干细胞样肿瘤细胞。因此,我们的空间分析表明,PD-L1 巨噬细胞通过激活干细胞样癌细胞中的 TGFβ 通路来维持 MRD,靶向这种相互作用可能防止 HCC 从 MRD 复发。